SecBot SecBot
SECBOTREPLAY Home › Report › TBPH

TBPH · Theravance Biopharma (TBPH) entered into a definitive merger agreement…

Theravance Biopharma, Inc. · 8-K filed Jun 29, 2026 at 06:30 ET

At the news

BULLISHIMPACT 7/10

8-K filed Jun 29, 2026 at 06:30 ET

Theravance Biopharma (TBPH) entered into a definitive merger agreement to be acquired by Zymeworks Inc. for $17.00 per share in cash plus one contingent value right (CVR) per share. The CVR entitles holders to 80% of net proceeds from any future monetization of ampreloxetine over ten years, plus a potential $50M milestone payment and 10% royalties on net sales. The all-cash deal values TBPH at approximately $929M equity value and is expected to close in H2 2026, subject to shareholder and regulatory approvals. The filing also includes employee communications (Item 7.01) and a press release (Item 8.01).

  • Shareholders to receive $17.00 per share in cash plus one CVR per share
  • CVR provides 80% of net proceeds from any ampreloxetine license/divestiture within 10 years post-close
  • CVR also includes a $50M aggregate milestone payment upon first commercial sale in a Major Market
  • CVR includes 10% royalty on net sales of ampreloxetine during the Royalty Term

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access